

## Adapting HIV Prevention Strategies to Changing Climates: A Review

\*Emmanuel Ifeanyi Obeagu<sup>1</sup>, Daniel Maada Mami<sup>2</sup> and Getrude Uzoma Obeagu<sup>3</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>Department of Community Medicine and Populations Health, University of Alabama, USA.

<sup>3</sup>School of Nursing Science, Kampala International University, Uganda

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Climate change poses significant challenges to global health, including the prevention of HIV/AIDS transmission. This paper explores the intersection of climate change and HIV prevention strategies, examining the implications of changing climates on the effectiveness of existing prevention interventions and identifying adaptation strategies to mitigate the impact of environmental changes on HIV transmission. By synthesizing existing research and best practices, this review aims to inform policymakers, healthcare providers, and communities about the importance of adapting HIV prevention strategies to changing climates and promoting resilience within vulnerable populations.

**Keywords:** *HIV prevention, climate change, adaptation strategies, public health, environmental health*

### Introduction

Climate change is a pressing global challenge with far-reaching implications for human health, including the prevention of HIV/AIDS transmission. As temperatures rise, rainfall patterns become more erratic, and extreme weather events increase in frequency and intensity, the dynamics of HIV transmission are being profoundly influenced. Understanding the intersection of climate change and HIV prevention strategies is critical for developing effective interventions that can adapt to the changing environmental conditions and mitigate the impact of climate variability on disease

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

transmission. The global HIV/AIDS epidemic remains a significant public health concern, with millions of new infections reported each year. Prevention efforts have traditionally focused on promoting safer sexual practices, increasing access to HIV testing and counseling, and scaling up biomedical interventions such as pre-exposure prophylaxis (PrEP) and voluntary medical male circumcision (VMMC). However, the effectiveness of these strategies may be compromised by the effects of climate change, which can exacerbate socio-economic vulnerabilities and increase the risk of HIV transmission among vulnerable populations. Climate change influences HIV transmission dynamics through various pathways, including changes in temperature and humidity levels, alterations in vector behavior, and disruptions to healthcare infrastructure. Higher temperatures and increased humidity can create favorable conditions for the survival and transmission of the virus, while extreme weather events such as floods and droughts can disrupt access to HIV prevention services and exacerbate social and economic inequalities. As a result, the ability to effectively prevent HIV transmission is increasingly being challenged by the impacts of climate change. Adapting HIV prevention strategies to changing climates requires a multi-faceted approach that addresses both the direct and indirect impacts of climate variability on disease transmission. This includes integrating climate resilience considerations into HIV/AIDS programming, mainstreaming climate risk assessments, and strengthening healthcare systems to enhance adaptive capacity and response mechanisms. Additionally, innovative approaches that leverage advances in technology, community engagement, and social mobilization are needed to address the unique challenges posed by the intersection of climate change and HIV/AIDS prevention.<sup>1-40</sup>

## Climate Change and HIV Transmission

Climate change significantly impacts the transmission dynamics of HIV/AIDS, presenting intricate challenges to global health. The nexus between climate change and HIV transmission is multifaceted, with environmental alterations influencing various aspects of disease spread. Understanding these dynamics is vital for crafting effective strategies to mitigate HIV transmission in the context of climate change. Directly, climate change affects HIV transmission by altering environmental conditions conducive to the survival and transmission of the virus. Changes in temperature and humidity levels can impact the viability of the virus in bodily fluids, potentially affecting its transmissibility. Moreover, shifts in rainfall patterns and water availability can influence hygiene practices and increase the risk of opportunistic infections among individuals living with HIV/AIDS. Indirectly, climate change exacerbates socio-economic vulnerabilities, amplifying the risk of HIV transmission within affected communities. Extreme weather events, such as floods, hurricanes, and droughts, disrupt livelihoods, displace populations, and strain healthcare systems. Displacement, in particular, can lead to overcrowded living conditions, limited access to healthcare, and heightened risk-taking behaviors, all of which facilitate HIV transmission. Migration patterns driven by climate change further complicate HIV transmission dynamics, as individuals move in search of safer environments or livelihood opportunities. Migration can lead to the spatial redistribution of HIV/AIDS, potentially exacerbating the epidemic in new areas. Moreover, migration disrupts social networks and support systems,

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. Elite Journal of Medicine, 2024; 2(4): 92-108

increasing vulnerability to HIV infection among migrants and host communities alike. To address the intersection of climate change and HIV transmission, adaptation strategies are essential. Strengthening healthcare systems to withstand climate-related disruptions, promoting access to HIV prevention and treatment services in vulnerable areas, and integrating climate resilience considerations into HIV/AIDS programming are crucial steps. Additionally, community-based approaches that empower individuals to address their own healthcare needs and build resilience to climate-related hazards can enhance adaptive capacity and reduce vulnerability to HIV/AIDS.<sup>41-70</sup>

### **Implications for HIV Prevention Strategies**

The implications of climate change for HIV prevention strategies are significant, requiring adaptation and innovation to effectively address the evolving dynamics of disease transmission. Climate change necessitates the adaptation of existing HIV prevention strategies to remain effective in changing environmental conditions. Traditional prevention methods, such as condom distribution, needle exchange programs, and behavior change interventions, may need to be modified to account for climate-related factors such as extreme weather events, population displacement, and access to resources. Adapting these strategies requires flexibility and innovation to ensure continued effectiveness in mitigating HIV transmission. Integrating climate resilience considerations into HIV prevention programs is essential for building adaptive capacity within communities. This involves identifying and addressing climate-related vulnerabilities that may exacerbate HIV transmission, such as inadequate access to clean water and sanitation, limited healthcare infrastructure, and socio-economic disparities. By mainstreaming climate resilience into HIV prevention efforts, programs can better respond to the complex challenges posed by climate change and enhance their impact on reducing HIV transmission. Climate change disproportionately affects vulnerable populations, including women, children, and marginalized communities, who are also at increased risk of HIV transmission. Tailoring HIV prevention strategies to address the specific vulnerabilities of these populations is essential for reducing disparities in HIV prevalence and improving health outcomes. This may involve targeted outreach, culturally sensitive interventions, and community-based approaches that empower individuals to protect themselves from HIV/AIDS in the face of changing climates. Strengthening healthcare systems is critical for ensuring the delivery of HIV prevention services amidst climate variability. Climate-related disruptions, such as extreme weather events and healthcare infrastructure damage, can hinder access to prevention resources and services, particularly in low-resource settings. Investing in resilient healthcare infrastructure, capacity-building initiatives, and emergency preparedness planning can enhance the resilience of health systems and ensure the continuity of HIV prevention efforts in the face of climate change. Leveraging technology and innovation can enhance the effectiveness of HIV prevention strategies in the context of climate change. Digital health solutions, telemedicine, and mobile health platforms offer opportunities to reach remote and vulnerable populations with essential prevention services, education, and support. Additionally, incorporating climate data and predictive modeling into HIV prevention planning can improve the targeting and allocation of resources to areas most at risk of HIV transmission due to climate-related factors.<sup>71-110</sup>

### **Adaptation Strategies**

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. Elite Journal of Medicine, 2024; 2(4): 92-108

Adaptation strategies are essential for mitigating the impact of climate change on HIV/AIDS transmission and ensuring the effectiveness of prevention efforts. These strategies encompass a range of interventions aimed at enhancing resilience, reducing vulnerability, and promoting health equity within communities. Investing in climate-resilient healthcare infrastructure is crucial for ensuring the continuity of HIV/AIDS services amidst climate variability. This involves retrofitting existing healthcare facilities to withstand climate-related hazards, such as floods, storms, and heatwaves, and incorporating climate resilience considerations into the design and construction of new facilities. By enhancing the resilience of healthcare infrastructure, adaptation strategies can minimize disruptions in service delivery and protect healthcare workers and patients from the impacts of climate change. Strengthening health systems is essential for building resilience and enhancing the capacity to respond to the intersecting challenges of climate change and HIV/AIDS. This includes investments in healthcare governance, management, and financing mechanisms to improve the delivery, quality, and accessibility of HIV/AIDS services. Integrating HIV/AIDS programming into broader health systems strengthening initiatives can enhance adaptive capacity and ensure the sustainability of HIV prevention efforts in the face of changing climates. Community-based adaptation strategies empower communities to address their own healthcare needs and build resilience to climate-related hazards. This involves engaging communities in adaptation planning, decision-making, and implementation processes to ensure that interventions are contextually appropriate and responsive to local priorities and vulnerabilities. By fostering community ownership and participation, adaptation strategies can enhance the effectiveness and sustainability of HIV prevention efforts and promote health equity within communities. Developing climate-smart HIV prevention interventions involves integrating climate resilience considerations into existing prevention strategies and programs. This includes identifying and addressing climate-related vulnerabilities that may exacerbate HIV transmission, such as inadequate access to clean water and sanitation, limited healthcare infrastructure, and socio-economic disparities. By mainstreaming climate resilience into HIV prevention efforts, adaptation strategies can enhance the effectiveness of interventions and reduce the impact of climate change on disease transmission. Continued research and innovation are essential for advancing knowledge and developing evidence-based adaptation strategies to address the complex challenges posed by climate change and HIV/AIDS. This includes conducting interdisciplinary research to understand the drivers of vulnerability, identify effective adaptation measures, and evaluate the impact of interventions. Investing in research and innovation can inform policy and practice and facilitate the development of scalable solutions to address the intersecting challenges of climate change and HIV/AIDS.<sup>111-130</sup>

### **Policy Implications and Future Directions**

Policy implications and future directions at the intersection of climate change and HIV/AIDS are crucial for addressing the complex challenges posed by these interconnected phenomena. Effective policies can help mitigate the impact of climate change on HIV/AIDS transmission, improve access to treatment and care, and promote health equity within communities. Policymakers should adopt integrated policy approaches that address both climate change and HIV/AIDS comprehensively. This includes mainstreaming climate resilience considerations into HIV/AIDS policies and programs and vice versa. Integrated approaches can leverage synergies, optimize

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. Elite Journal of Medicine, 2024; 2(4): 92-108

resource allocation, and enhance the effectiveness of interventions aimed at reducing vulnerability to both climate change and HIV/AIDS. Strengthening healthcare systems is critical for ensuring the delivery of HIV/AIDS services amidst climate variability. Policymakers should prioritize investments in healthcare infrastructure, equipment, and human resources to enhance service delivery, capacity, and quality of care. Improving healthcare governance, management, and financing mechanisms is essential for building resilient health systems that can effectively respond to the evolving challenges posed by climate change and HIV/AIDS. Policymakers should prioritize adaptation and resilience-building initiatives aimed at reducing vulnerability to climate change and HIV/AIDS within communities. This includes investing in climate-resilient infrastructure, promoting sustainable land-use practices, and strengthening social protection mechanisms to enhance community resilience. Additionally, promoting adaptive livelihood strategies, such as climate-smart agriculture and alternative income-generating activities, can help communities cope with the impacts of climate change and reduce their susceptibility to HIV/AIDS. Mainstreaming gender equality and social inclusion considerations is essential for addressing the differential impacts of climate change and HIV/AIDS on marginalized populations, including women, children, and LGBTQ+ individuals. Policymakers should prioritize gender-responsive policies and programs that address the specific vulnerabilities of these populations, including access to healthcare services, education, and economic opportunities. Promoting women's empowerment, gender equality, and social inclusion can enhance resilience, reduce vulnerability, and improve health outcomes in the face of climate change and HIV/AIDS. Continued research and innovation are essential for advancing knowledge and developing evidence-based strategies to address the complex challenges posed by climate change and HIV/AIDS. Policymakers should support interdisciplinary research initiatives that explore the underlying drivers of vulnerability, identify effective adaptation strategies, and evaluate the impact of policy interventions. Investing in research and innovation can inform policy and practice and facilitate the development of scalable solutions to address both climate change and HIV/AIDS. International cooperation and partnerships are essential for addressing the global challenges of climate change and HIV/AIDS. Policymakers should prioritize multilateral collaboration, knowledge-sharing, and capacity-building initiatives to support countries in implementing climate-resilient HIV/AIDS programs and strengthening health systems. International cooperation can facilitate the mobilization of resources, transfer of technology, and exchange of best practices to enhance resilience and promote sustainable development outcomes worldwide.<sup>131-154</sup>

## Conclusion

The intersection of climate change and HIV/AIDS presents complex challenges that require comprehensive and integrated approaches to address. It is evident that climate change significantly influences the transmission dynamics of HIV/AIDS, exacerbating vulnerability and increasing the risk of disease spread within communities. The impacts of climate change on healthcare infrastructure, socio-economic conditions, and population movements pose unique challenges to HIV/AIDS prevention and treatment efforts, necessitating adaptive responses at local, national, and global levels. Adaptation strategies play a crucial role in mitigating the impact of climate change on HIV/AIDS and promoting resilience within affected populations. Strengthening healthcare systems, integrating climate resilience into HIV/AIDS programming, promoting

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108



community-based adaptation, and investing in research and innovation are essential steps towards building adaptive capacity and reducing vulnerability to the intersecting challenges of climate change and HIV/AIDS.

## References

1. McMichael AJ. Planetary overload: global environmental change and the health of the human species. Cambridge University Press; 1993.
2. Reser JP, Swim JK. Adapting to and coping with the threat and impacts of climate change. *American Psychologist*. 2011;66(4):277.
3. Irwin AC, Millen JV, Fallows D. Global AIDS: myths and facts: tools for fighting the AIDS pandemic. South End Press; 2003.
4. Snowden FM. Emerging and reemerging diseases: a historical perspective. *Immunological reviews*. 2008;225(1):9-26.
5. Russell BS, Eaton LA, Petersen-Williams P. Intersecting epidemics among pregnant women: alcohol use, interpersonal violence, and HIV infection in South Africa. *Current HIV/AIDS Reports*. 2013; 10:103-110.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916. [https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
17. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
18. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
19. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov*. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
21. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
22. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices of HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res*. 2018;6(1):1-4.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://epjournals.com/journals/EJM/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)

23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
25. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://epjournals.com/journals/EJM/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
26. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
27. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
29. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://epjournals.com/journals/EJM/links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
30. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://epjournals.com/journals/EJM/links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
31. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://epjournals.com/journals/EJM/links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
32. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014)

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108



[https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfected with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)

33. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
34. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
35. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
36. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
38. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
39. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
40. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
41. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. Elite Journal of Medicine, 2024; 2(4): 92-108

42. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
43. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
44. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
45. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.  
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
46. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
47. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
48. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
49. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
50. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
51. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
52. Arthur RF, Gurley ES, Salje H, Bloomfield LS, Jones JH. Contact structure, mobility, environmental impact and behaviour: the importance of social forces to infectious disease dynamics and disease ecology. *Philosophical Transactions of the Royal Society B: Biological Sciences.* 2017;372(1719):20160454.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

53. Oramasionwu CU, Daniels KR, Labreche MJ, Frei CR. The environmental and social influences of HIV/AIDS in sub-Saharan Africa: a focus on rural communities. *International journal of environmental research and public health*. 2011;8(7):2967-2979.
54. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
55. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
56. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
57. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
58. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
59. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
60. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
61. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
62. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
63. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
64. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
65. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

66. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
67. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
68. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
69. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
70. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
71. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.
72. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):46-58.
73. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine.* 2024;2(1):35-46.
74. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;*12(01).
75. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV.* 2024;2(1):65-78.
76. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;*12(01).
77. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV.* 2024;2(1):31-50.
78. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV.* 2024;2(1):1-5.
79. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
80. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences.* 2024;4(1):32-7.
81. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences.* 2024;4(1):38-44.
82. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science.* 2024;2(1):33-42.
83. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology.* 2024;2(1):26-41.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

84. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
85. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
86. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
87. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
88. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
89. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
90. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijiar.com>;12(01).
91. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
92. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
93. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
94. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
95. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
96. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
97. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
98. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
99. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
100. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108



101. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
102. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
103. Obeagu EI, Amaeze AA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
104. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
105. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
106. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
107. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
108. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: http://www.journalijar.com*;12(01).
109. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: http://www.journalijar.com*;12(01).
110. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
111. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
112. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
113. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
114. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
115. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
116. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
117. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

118. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
119. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
120. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
121. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
122. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
123. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
124. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
125. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
126. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
127. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
128. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
129. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-5.
130. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
131. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
132. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
133. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
134. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.

135. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
136. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
137. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
138. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
139. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
140. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
141. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
142. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
143. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
144. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
145. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):111-117.
146. Brault MA, Vermund SH, Aliyu MH, Omer SB, Clark D, Spiegelman D. Leveraging HIV care Infrastructures for integrated chronic disease and pandemic management in sub-Saharan Africa. *International journal of environmental research and public health*. 2021;18(20):10751.
147. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, Bartos M, Ghys PD, Opuni M, Barr D, Alsallaq R. Towards an improved investment approach for an effective response to HIV/AIDS. *The Lancet*. 2011;377(9782):2031-2041.
148. Watkins-Hayes C. Intersectionality and the sociology of HIV/AIDS: Past, present, and future research directions. *Annual Review of Sociology*. 2014; 40:431-457.
149. Nyasimi M, Ayanlade A, Mungai C, Derkyi M, Jegede MO. Inclusion of gender in Africa's climate change policies and strategies. *Handbook of Climate Change Communication: Vol. 1: Theory of Climate Change Communication*. 2018:171-85.

**Citation:** Obeagu EI, Mami DM, Obeagu GU. Adapting HIV Prevention Strategies to Changing Climates: A Review. *Elite Journal of Medicine*, 2024; 2(4): 92-108

150. Braaf R. Addressing the intersections of climate change, energy, environmental degradation and gender-based violence. Prepared for the United Nations Development Programme. Accessed on November. 2016; 12:2022.
151. Obeagu EI, Mami DM, Obeagu GU. Climate Change as a Driver of HIV Transmission Dynamics: A Review. Elite Journal of HIV, 2024; 2(4): 110-127
152. Obeagu EI, Mami DM, Obeagu GU. The Nexus Between Climate Change and HIV Spread: Understanding Intersections, Impacts, and Interventions. Elite Journal of HIV, 2024; 2(4): 128-145
153. Obeagu EI, Mami DM, Obeagu GU. Climate Change and HIV: Assessing Risks and Vulnerabilities. Elite Journal of Public Health, 2024; 2 (4): 94-110
154. Obeagu EI, Mami DM, Obeagu GU. Climate Variability and HIV: Implications for Control Measures. Elite Journal of Public Health, 2024; 2 (4): 111-127